| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Wu Jun Lan CEO | XSHE Exchange | CNE100000GF1 ISIN |
| CN Country | 5,297 Employees | 15 Jul 2026 Last Dividend | 26 Oct 2016 Last Split | 30 Oct 2009 IPO Date |
Tianjin Chase Sun Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical company that has been at the forefront of healthcare innovation since its establishment in 1996. With its headquarters in Tianjin, China, the company has grown to have a wide-reaching impact both domestically and internationally. Its core activities encompass the research, development, production, and marketing of a diverse range of pharmaceutical products. By focusing on critical healthcare segments, Tianjin Chase Sun aims to contribute significantly to improving the quality of life for patients worldwide, exhibiting a strong commitment to addressing pressing health issues with effective solutions.
Tianjin Chase Sun Pharmaceutical Co., Ltd. offers a diverse portfolio of products and services tailored to meet the complex needs of the healthcare industry, including:
Focusing on areas such as severe disease, cardiovascular, cerebrovascular system, respiratory system, neurodegenerative conditions, and anti-tumor treatments, Tianjin Chase Sun Pharmaceutical Co., Ltd. is dedicated to advancing healthcare outcomes through innovation and quality.